Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387257167> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W4387257167 endingPage "54" @default.
- W4387257167 startingPage "50" @default.
- W4387257167 abstract "Kidney diseases are quite common among cats, especially age-related ones. The article describes a study on comparative efficacy and safety of the drug Nephrospas, developed by «AVZ Ltd», Russia), which contains telmisartan and excipients and the drug Semintra®, developed by «Boehringer Ingelheim Vetmedica GmbH» (Germany), which also contains telmisartan as an active ingredient.
 Purpose of the study. To evaluate the clinical efficacy and safety of the drug Nefrospas in the treatment of cats with systemic hypertension and concomitant kidney disease (chronic kidney disease) stages 1-3 in comparison with the drug Semintra®.
 Materials and methods. The studies were carried out on 40 cats of different breeds aged 5 to 16 years, weighing 2.1…8.5 kg with arterial hypertension accompanied by chronic kidney disease, idiopathic hypertension, CKD and hyperparathyroidism. 2 groups of animals were formed: 1 experimental (Nefrospas) and 2 control or comparison (Semintra®), 10 animals in each group.
 Results and Conclusions. According to the results of comparative characteristic of the medicinal preparation Nefrospas with the analogue preparation, positive dynamics of reduction of total protein concentration, normalisation of pressure and increase of urine specific gravity were observed. This fact indicates restoration of functional activity of kidneys.
 The results of the clinical study of Nefrospas in cats with CKD of 1-3 degree according to IRIS classification demonstrated safety and efficacy of this drug for correction of hyposthenuria and nephrotoxic proteinuria.
 Summarising the results, we can conclude about the therapeutic equivalence and interchangeability of the domestic drug Nefrospas and foreign drug Semintra®. Nefrospas has shown similar results in the treatment of kidney diseases in cats, therefore its use is possible as a worthy alternative to the foreign drug." @default.
- W4387257167 created "2023-10-03" @default.
- W4387257167 creator A5007095499 @default.
- W4387257167 creator A5019974313 @default.
- W4387257167 creator A5045193575 @default.
- W4387257167 date "2023-10-02" @default.
- W4387257167 modified "2023-10-03" @default.
- W4387257167 title "Comparative effectiveness of Nephrospas and Semintra® in kidney diseases in cats" @default.
- W4387257167 doi "https://doi.org/10.32416/2500-4379-2023-3-50-54" @default.
- W4387257167 hasPublicationYear "2023" @default.
- W4387257167 type Work @default.
- W4387257167 citedByCount "0" @default.
- W4387257167 crossrefType "journal-article" @default.
- W4387257167 hasAuthorship W4387257167A5007095499 @default.
- W4387257167 hasAuthorship W4387257167A5019974313 @default.
- W4387257167 hasAuthorship W4387257167A5045193575 @default.
- W4387257167 hasConcept C126322002 @default.
- W4387257167 hasConcept C149172746 @default.
- W4387257167 hasConcept C2778653478 @default.
- W4387257167 hasConcept C2779561371 @default.
- W4387257167 hasConcept C2779716603 @default.
- W4387257167 hasConcept C2779904517 @default.
- W4387257167 hasConcept C2780035454 @default.
- W4387257167 hasConcept C2780091579 @default.
- W4387257167 hasConcept C71924100 @default.
- W4387257167 hasConcept C84393581 @default.
- W4387257167 hasConcept C98274493 @default.
- W4387257167 hasConceptScore W4387257167C126322002 @default.
- W4387257167 hasConceptScore W4387257167C149172746 @default.
- W4387257167 hasConceptScore W4387257167C2778653478 @default.
- W4387257167 hasConceptScore W4387257167C2779561371 @default.
- W4387257167 hasConceptScore W4387257167C2779716603 @default.
- W4387257167 hasConceptScore W4387257167C2779904517 @default.
- W4387257167 hasConceptScore W4387257167C2780035454 @default.
- W4387257167 hasConceptScore W4387257167C2780091579 @default.
- W4387257167 hasConceptScore W4387257167C71924100 @default.
- W4387257167 hasConceptScore W4387257167C84393581 @default.
- W4387257167 hasConceptScore W4387257167C98274493 @default.
- W4387257167 hasIssue "3" @default.
- W4387257167 hasLocation W43872571671 @default.
- W4387257167 hasOpenAccess W4387257167 @default.
- W4387257167 hasPrimaryLocation W43872571671 @default.
- W4387257167 hasRelatedWork W153873952 @default.
- W4387257167 hasRelatedWork W1986027462 @default.
- W4387257167 hasRelatedWork W2347860385 @default.
- W4387257167 hasRelatedWork W2588468355 @default.
- W4387257167 hasRelatedWork W2969970070 @default.
- W4387257167 hasRelatedWork W2976756887 @default.
- W4387257167 hasRelatedWork W2997518748 @default.
- W4387257167 hasRelatedWork W4361293408 @default.
- W4387257167 hasRelatedWork W4378639815 @default.
- W4387257167 hasRelatedWork W2186173324 @default.
- W4387257167 hasVolume "2023" @default.
- W4387257167 isParatext "false" @default.
- W4387257167 isRetracted "false" @default.
- W4387257167 workType "article" @default.